What this panel supports, and what it does not

What is supported: the mineral-axis and secondary-cause screen can narrow evidence about a treatable contributor to bone loss, and a properly collected, properly compared bone-turnover marker can show that remodeling activity changed between two time points. Bone-turnover marker changes generally occur earlier than a measurable DXA change and can support an assessment of pharmacodynamic response or adherence once comparability is established.

What is not supported: no result in this panel, alone or combined, diagnoses osteoporosis or quantifies fracture risk. That determination stays with DXA bone mineral density (T-score -2.5 or lower at femoral neck, total hip, or lumbar spine) or a documented recognized low-trauma fracture site meeting the cited diagnostic criteria. A normal total ALP or BSAP does not exclude low bone mass, and a striking serial CTX change does not establish a treatment response unless the comparability checks worked through in the guided case actually hold.

What depends on method and local policy: the exact reference interval, units, and least significant change printed on a laboratory's own report come from that laboratory's validated instrument, reagent, and software combination, not from a manufacturer example or a national guideline. whether BSAP is offered as its own order, how a CTX fasting requirement is communicated to collection staff, and local specimen-rejection criteria all vary by laboratory.

A laboratory result can describe a rate or support or argue against a contributor, but it cannot substitute for the scan that makes the diagnosis, and it cannot substitute for method-matched, time-matched collection when a serial comparison is the question being asked.